To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings

International Journal of Cancer

Volumn 140, Issue 6, 2017, Pages 1293-1305

  Campos, Nicole G ^a   Tsu, Vivien ^b   Jeronimo, Jose ^b   Mvundura, Mercy ^b   Lee, Kyueun ^a,c   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b PATH   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

cancer screening; cervical cancer; economic evaluation; health disparities; HPV DNA test; human papillomavirus; Uganda

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE ACCESS; HEALTH DISPARITY; MATHEMATICAL MODEL; PAPILLOMAVIRUS INFECTION; QUANTITATIVE ANALYSIS; RISK REDUCTION; UGANDA; UTERINE CERVIX CANCER; ADULT; CARCINOMA, SQUAMOUS CELL; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; EARLY CANCER DIAGNOSIS; ECONOMIC MODEL; ECONOMICS; FEMALE; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HUMAN; ISOLATION AND PURIFICATION; LIFE EXPECTANCY; MASS SCREENING; MONTE CARLO METHOD; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

VIRUS DNA;

ADULT; CARCINOMA, SQUAMOUS CELL; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HEALTH POLICY; HEALTHCARE DISPARITIES; HUMANS; LIFE EXPECTANCY; MASS SCREENING; MODELS, ECONOMIC; MONTE CARLO METHOD; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK REDUCTION BEHAVIOR; UGANDA; UTERINE CERVICAL NEOPLASMS;

EID: 85010780423     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30551     Document Type: Article

References (45)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], 2013, International Agency for Research on Cancer: Lyon, France.
2. “FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV.” FDA News Release December 11, 2014; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm.
3. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247–55.
4. Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011;1:408–19.
5. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459–66.
6. Gavi the Vaccine Alliance. Disbursements and commitments. Accessed on March 31, 2016. Available from: http://www.gavi.org/results/disbursements/.
7. World Health Organization. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. World Health Organization: Geneva, 2013.
8. Weidemaier K, Carrino J, Curry A, et al. Advancing rapid point-of-care viral diagnostics to a clinical setting. Future Virol 2015;10:313–28.
9. Campbell C, Kafwafwa S, Brown H, et al. Use of thermo-coagulation as an alternative treatment modality in a 'screen and treat' programme of cervical screening in rural Malawi. Int J Cancer 2016;139:908–15.
10. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868–73.
11. Sowjanya AP, Paul P, Vedantham H, et al. Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. Cancer. Epidemiol Biomarkers Prev 2009;18:1373–78.
12. Moses E, Pedersen HN, Mitchell SM, et al. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Trop Med Int Health 2015;20:1355–67.
13. Arrossi S, Thouyaret L, Herrero R, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health 2015;3:e85–94.
14. Campos NG, Tsu V, Jeronimo J, et al. When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res 2015;1:38–58.
15. Campos NG, Burger EA, Sy S, et al. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 2014;180:545–55.
16. Jeronimo J, Bansil P, Lim J, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer 2014;24:576–85.
17. Mvundura M, Tsu V. Estimating the costs of cervical cancer screening in high-burden sub-Saharan African countries. Int J Gynaecol Obstet 2014;126:151–55.
18. World Health Organization. Macroeconomics and health: Investing in health for economic development: Report of the Commission on Macroeconomics and Health. World Health Organization: Geneva, 2001.
19. Tan-Torres Edejer T, Baltussen, R., Adam, T., Hutubessy, R., Acharya, A., Evans, D.B., Murray, C.J.L., eds. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization: Geneva, 2003.
20. Jamison DT, Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A., Musgrove, P., eds. Disease control priorities in developing countries. 2nd ed., Oxford University Press and The World Bank: Washington, D.C., 2006.
21. Gold MR. Cost-effectiveness in health and medicine. Oxford University Press: New York, 1996.
22. Campos NG, Maza M, Alfaro K, et al. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer 2015;137:893–902.
23. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077–87.
24. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010;11:165–73.
25. Surveillance Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases Nov 2011 Sub (1973-2009 varying) – Linked to County Attributes – Total U.S., 1969-2010 Counties.
26. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007;166:137–50.
27. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007;5:11.
28. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997;17:483–89.
29. Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2013;120:218–23.
30. Cremer M, Bullard K, Maza M, et al. Cytology versus visual inspection with acetic acid among women treated previously with cryotherapy in a low-resource setting. Int J Gynaecol Obstet 2010;111:249–52.
31. Chirenje ZM, Rusakaniko S, Kirumbi L, et al. Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ 2001;79:127–32.
32. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158–68.
33. Campos NG, Kim JJ, Castle PE, et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2012;130:2672–84.
34. United Nations Development Programme. International Human Development Indicators. 2014. Available from: http://hdr.undp.org/en/data.
35. Kim JJ, Campos NG, Sy S, et al. Inefficiencies and high-value improvements in U.S. cervical cancer screening practice: A cost-effectiveness analysis. Ann Intern Med 2015;163:589–97.
36. Cervical Cancer Action. Global Progress in HPV DNA Testing for Cervical Cancer Screening. Available from: http://www.cervicalcanceraction.org/comments/comments2.php.
37. World Development Indicators, 2016, World Bank. Available from: http://data.worldbank.org/data-catalog/world-development-indicators.
38. Coleman JS, Cespedes MS, Cu-Uvin S, et al. An insight into cervical cancer screening and treatment capacity in sub Saharan Africa. J Low Genit Tract Dis 2016;20:31–7.
39. Kumakech E, Andersson S, Wabinga H, et al. Integration of HIV and cervical cancer screening perceptions of healthcare providers and policy makers in Uganda. BMC Public Health 2014;14:810.
40. Kumakech E, Andersson S, Wabinga H, et al. Integration of HIV and cervical cancer screening perceptions and preferences of communities in Uganda. BMC Womens Health 2015;15:23.
41. Joshi S, Sankaranarayanan R, Muwonge R, et al. Screening of cervical neoplasia in HIV-infected women in India. Aids 2013;27:607–15.
42. Safaeian M, Kiddugavu M, Gravitt PE, et al. Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Sex Transm Infect 2008;84:306–11.
43. Asiimwe S, Whalen CC, Tisch DJ, et al. Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda. Int J STD AIDS 2008;19:605–10.
44. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120–30.
45. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006;118:985–90.